Patrick DalyAnemia | March 1, 2024
Fludarabine, cyclophosphamide, and ATG had superior outcomes versus historical outcomes of non-ATG conditioning.
Read More
Patrick DalyPolycythemia Vera | March 1, 2024
Dr. Grunwald of the Atrium Health Levine Cancer Institute, discusses caring for patients with PV on rare disease day.
Patrick DalyPNH | February 29, 2024
Danicopan as an add-on to C5 inhibitor therapy in patients with PNH with EVH showed sustained treatment benefits.
Sarah Valentinevon Willebrand Disease | February 28, 2024
Study finds a possible negative association between hemoglobin levels and certain von Willebrand factor assays.
Zahra Pakbaz, MDSickle Cell Disease | February 27, 2024
Dr. Pakbaz describes some of the difficulties faced by patients with SCD as they switch from pediatric to adult programs.
Heme Today Staff WritersAnemia | February 26, 2024
This would be the fourth authorized indication for luspatercept in the European Union.
Patrick DalySickle Cell Disease | February 26, 2024
Reduction of hemolysis significantly predicted postinfusion transduction efficacy in patients with SCD treated with lovo-cel.
Melissa BadamoSickle Cell Disease | February 22, 2024
Exa-cel eliminated RBC transfusions in patients with transfusion-dependent β-thalassemia.
Patrick DalyAnemia | February 22, 2024
HSCT with a matched unrelated or haploidentical donor was a promising alternative in patients with severe aplastic anemia.
Melissa BadamoSickle Cell Disease | February 21, 2024
Hydroxyurea therapy reduced blood transfusion by 75% among pediatric patients in sub-Saharan Africa with sickle cell anemia.
Patrick DalyHematology | February 20, 2024
The US FDA extended the Priority Review period for the BLA for marnetegragene autotemcel in leukocyte adhesion deficiency-I.
Patrick DalySickle Cell Disease | February 20, 2024
The European Commission has approved the Conditional Marketing Authorization for exagamglogene autotemcel.
Patrick DalyAnemia | February 21, 2024
Low hemoglobin and anemia were found to be modifiable risk factors associated with low cognitive function in older patients.
Patrick DalyHemophilia | February 21, 2024
Desmopressin with FVIII during operations was reportedly feasible and safe in patients with nonsevere hemophilia A.
Patrick DalyAnemia | February 14, 2024
C1-inhibitor administration during transfusions did not significantly suppress hemolysis in autoimmune hemolytic anemia.
Patrick DalySickle Cell Disease | February 13, 2024
Drs. Grant, Sutin, and Lin discuss their pilot study investigating cerebral hemodynamics in infants with sickle cell disease.
Melissa BadamoVTE | February 12, 2024
Patients with RA had a 57% increased risk of VTE; a 58% increased risk of DVT; and a 57% increased risk of PE.
Patrick DalyDeep Vein Thrombosis | February 9, 2024
Thrombectomy treatment of iliofemoral DVT reduced the incidence of post-thrombotic syndrome compared with anticoagulants.
John Strouse, MD, PhDSickle Cell Disease | February 15, 2024
Dr. Pakbaz and Dr. Strouse discuss their experiences practicing classical hematology and where the speciality is heading.
Patrick DalyPNH | February 6, 2024
The majority of newly diagnosed patients with PNH did not receive a PNH-specific therapy at diagnosis.
Latest News

March 1, 2024